Sio Gene Therapies Inc - SIOX stock
About[edit]
Sio Gene Therapies Inc. is a clinical-stage company dedicated to advancing gene therapies for neurodegenerative diseases, with a focus on radically transforming the lives of patients. The company has entered into license agreements with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School to develop and commercialize gene therapy products, including AXO-Lenti-PD, AXO-AAV-GM1, and AXO-AAV-GM. Formerly known as Axovant Gene Therapies Ltd., the company changed its name to Sio Gene Therapies, Inc. in November 2020, and it is headquartered in New York, New York.[1]
History[edit]
Sio Gene Therapies Inc. was incorporated in 2014 in the United States. The company's origin lies in its establishment as a clinical-stage biotechnology company focused on developing gene therapies to address neurodegenerative diseases.[2]
Initially known as Axovant Gene Therapies Ltd., the company later underwent a name change to Sio Gene Therapies, Inc. in November 2020. This change reflected the company's continued commitment to advancing gene therapies and its evolving focus on addressing neurodegenerative conditions to improve the lives of patients.[3]
As a clinical-stage company, Sio Gene Therapies has been actively involved in research and development efforts to advance its gene therapy candidates. These include AXO-Lenti-PD, a gene therapy product developed under a license agreement with Oxford BioMedica (UK) Ltd., and AXO-AAV-GM1 and AXO-AAV-GM, which are being developed under a license agreement with The University of Massachusetts Medical School.[3]
With a focus on advancing transformative gene therapies for neurodegenerative diseases, Sio Gene Therapies seeks to drive research, clinical trials, and collaborations to provide innovative treatment options for patients with these challenging conditions.[4]
Dissolution[edit]
Shareholders voted to dissolve the company in April, 2023. The following message was posted to their website:[5]
"On April 5, 2023, the stockholders of Sio Gene Therapies, Inc. voted to liquidate and dissolve the company. The activities necessity to complete the liquidation are being conducted by former employees of the company now engaged as consultants, working with various outside vendors, including attorneys and tax accountants. The company expects to pay at least one liquidating dividend to its stockholders, however, the amount and timing of the dividend is still undetermined."
A Plan of Complete Liquidation and Dissolution was filed with the SEC, which detailed the liquidation of assets and distribution of the proceeds.[6]
- ↑ Yahoo Finance. SIOX Stock Profile. Retrieved on 10/1/2023.
- ↑ Pitchbook. Sio Gene Profile. Retrieved on 10/1/2023.
- ↑ 3.0 3.1 Wikipedia. Sio Gene Therapies. Retrieved on 10/1/2023.
- ↑ siogtx.com. Investors. Retrieved on 10/1/2023.
- ↑ siogtx.com. Home. Retrieved on 10/14/2023.
- ↑ SEC.gov. PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION. Accessed on 10/14/2023.
